Solutions
Infectious Disease
One-stop Central Lab Services
Integrated Pathogen Laboratory Solutions to empower infectious disease study
Teddylab offers clinical trial infectious disease testing capability for bacterial pathogens and viral infectious agents. We also have the scientific and technical expertise available to work on study specific methodologies and assay development with our Bioanalytical and Genomics Laboratories.
Teddylab has accumulated rich project experience in respiratory infection (Covid-19, RSV), sexually transmitted disease and building hepatitis diagnostic center.
Due to the Covid-19 epidemic, the development of Covid-19 drugs and vaccines has become a hot track for clinical trials of new drugs seeing related demand risen sharply. For drug treating Covid-19, Teddylab participated in the domestic clinical research of Remdesivir and Kaletra; for the clinical trials of Covid-19 vaccines, Teddylab reserves a series of related testing technologies through independent research and development which are used in vaccine clinical trials to monitor the efficacy, immunogenicity, PK/PD data, and genotyping of virus strains.
RSV (respiratory syncytial virus) is a common respiratory virus that usually causes mild cold-like symptoms. Most young adults can recover within one to two weeks. But for vulnerable groups such as infants and the elderly, the threat of RSV can be fatal. WHO estimates that as a major cause of child mortality, RSV infects 64 million children and causes death of 160,000 children worldwide every year. Teddylab has accumulated rich test experience in RSV vaccine project. With methodological transfer and cross-validation with foreign laboratories, Teddylab uses respiratory co-pathogen kits to quickly test pathogens, conduct A and B subtype analysis, viral load and quantitative analysis, as well as cellular and humoral immunity, and verify the effectiveness of the vaccine.
Viral hepatitis is an infectious liver disease mainly caused a variety of hepatitis viruses. At present, five types of hepatitis A, B, C, D and E have been recognized. As early as the initial stage of its establishment, Teddylab assisted with R&D of Ascletis Pharmaceuticals-developed and the State Food and Drug Administration of China-approved Class 1 hepatitis C new drug danoprevir sodium tablets. As of 2022, Teddylab has participated in dozens of clinical research projects on viral hepatitis including hepatitis B and C, as well as fatty liver and liver cancer, and has established a good cooperative relationship with infectious disease experts.
HPV infection is a viral infection that usually causes growths (warts) on the skin or mucous membranes. At present, the research and development of HPV vaccine is in full swing. Teddylab is the central laboratory of several domestic HPV vaccine phase III clinical trial in China with excellent HPV typing, HPV mRNA E6/E7 detection, cell TCT test and vaginal microscopic histopathological evaluation.
